Tislelizumab plus Bevacizumab

DRUG4 trials

Sponsors

Henan Provincial People's Hospital

Conditions

Astrocytoma of BrainGlioblastomaOligodendrogliomaRecurrent Glioblastoma

Phase 2

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma

Not yet recruitingNCT05502991

Henan Provincial People's HospitalGlioblastoma

Start: 2022-12-11End: 2027-12-31Target: 60Updated: 2022-09-27

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

RecruitingNCT05512351

Henan Provincial People's HospitalOligodendroglioma

Start: 2022-12-23End: 2026-12-31Target: 80Updated: 2022-09-27

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

Not yet recruitingNCT05518994

Henan Provincial People's HospitalAstrocytoma of Brain

Start: 2022-12-01End: 2027-12-31Target: 70Updated: 2022-09-27

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Not yet recruitingNCT05540275

Henan Provincial People's HospitalRecurrent Glioblastoma

Start: 2023-10-05End: 2026-12-31Target: 30Updated: 2023-10-06

Related Papers

Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab

Journal of Cancer Research and Clinical Oncology2024-10-184 citations

Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.

2024-08-066 citations